Lupron for Prostate Cancer: How Leuprolide Works, Side Effects & Testosterone Flare

What Is Lupron?

Lupron Depot is the brand name for a depot formulation of leuprolide acetate.

Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist, also called an LHRH agonist.

Current U.S. prescribing information indicates Lupron Depot for the treatment of advanced prostate cancer.

It is one of several forms of medical androgen deprivation therapy.

How Does Lupron Work?

Normally, the hypothalamus and pituitary stimulate the testicles to produce testosterone.

When Lupron is first given, it initially stimulates the pituitary GnRH receptors. This briefly increases luteinizing hormone (LH) and testosterone.

With continued exposure, those receptors become desensitized and downregulated. LH production then falls dramatically, and the testicles stop producing most of their testosterone.

Current Lupron prescribing information reports that testosterone generally falls to the traditional castrate range of below 50 ng/dL within about four weeks.

Modern EAU guidance notes that many men on ADT achieve even lower levels, below 20 ng/dL.

Does Lupron Kill Prostate Cancer Cells?

Not in the same way as chemotherapy.

Most prostate-cancer cells initially depend heavily on androgen-receptor signaling. By reducing circulating testosterone, Lupron removes one of the major growth signals.

This can:

• lower PSA;
• slow tumour growth;
• reduce cancer-related symptoms;
• help control bone or lymph-node metastases;
• reduce the risk of complications such as obstruction; and
• improve outcomes when combined with other treatments in appropriate settings.

But prostate cancer can eventually adapt and progress despite castrate testosterone levels. This is called castration-resistant prostate cancer.

Is Lupron Palliative or Curative?

The old page describes Lupron only as a drug that relieves symptoms. That is incomplete.

Lupron can certainly be used palliatively in advanced metastatic disease, but ADT also has important roles in treatment designed to improve long-term cancer control.

For example, ADT may be combined with radiotherapy in selected:

• unfavorable intermediate-risk disease;
• high-risk localized disease;
• locally advanced disease; and
• node-positive disease.

In metastatic disease, ADT is the hormonal backbone of systemic treatment.

So the correct statement is:

How Is Lupron Depot Given?

The old version described daily subcutaneous Lupron injections as though they were the main prostate-cancer regimen.

Current U.S. prostate-cancer labeling for Lupron Depot uses scheduled intramuscular depot injections administered by a healthcare provider:

The depot strengths are not interchangeable simply by adding or dividing doses because their release characteristics differ.

What Is Testosterone Flare?

Testosterone flare is one of the most important issues when starting a GnRH agonist such as Lupron.

During the first days after the initial injection, testosterone rises temporarily before falling.

Current Lupron labeling reports an increase of approximately 50% above baseline during the initial period.

EAU describes the surge as usually beginning within about 2–3 days and lasting approximately one week.

What Symptoms Can Flare Cause?

In men with advanced disease, the temporary androgen surge can worsen:

• bone pain;
• urinary obstruction;
• hematuria;
• ureteral obstruction;
• neurological symptoms; and
• spinal cord compression.

How Is Lupron Flare Prevented?

For patients judged to be at meaningful risk of clinical flare, clinicians may use a short course of an older androgen-receptor blocker around the time Lupron is started.

Current EAU guidance recommends short-term older-generation AR-antagonist therapy for selected metastatic patients starting an LHRH agonist to reduce flare risk.

However, not every patient needs flare prophylaxis, and GnRH antagonists such as degarelix or relugolix do not cause the same initial testosterone surge.

Where Does Lupron Fit in Modern Metastatic Treatment?

This has changed substantially.

For most fit men with metastatic hormone-sensitive prostate cancer, modern treatment usually does not consist of Lupron alone.

ADT is commonly combined with an androgen-receptor pathway inhibitor such as:

• abiraterone plus prednisone;
• apalutamide;
• enzalutamide; or
• darolutamide in appropriate settings.

Selected chemotherapy-fit patients may receive triplet therapy with:

• ADT;
• docetaxel; and
• an appropriate ARPI.

See our modern prostate cancer drugs guide.

Is Lupron Continued When Cancer Becomes Castration-Resistant?

Usually, yes.

Current Lupron labeling states that GnRH-analogue treatment is generally continued after development of non-metastatic or metastatic castration-resistant prostate cancer.

Additional systemic treatments are then layered onto the ongoing ADT according to previous therapy, disease burden and tumour biology.

What Are the Common Side Effects of Lupron?

Many adverse effects result from long-term testosterone suppression rather than from the injection itself.

Commonly reported effects include:

• hot flashes and sweating;
• reduced libido;
• erectile dysfunction;
• testicular shrinkage;
• fatigue/weakness;
• general or joint pain;
• injection-site pain or reaction;
• gastrointestinal symptoms;
• urinary symptoms; and
• body-composition and metabolic changes.

In trials of the 22.5 mg three-month depot, current U.S. labeling reported hot flashes/sweats in 58.5%, general pain in 26.6%, testicular atrophy in 20.2%, GI disorders in 16.0%, urinary disorders in 14.9% and injection-site reactions in 13.8%.

Sexual Side Effects

Reducing testosterone to castrate levels commonly affects sexual function.

Possible effects include:

• loss of sexual desire;
• erectile dysfunction;
• reduced spontaneous erections;
• testicular atrophy; and
• fertility impairment.

These are expected physiological consequences of androgen deprivation rather than evidence that the cancer itself is necessarily worsening.

Hot Flashes

Hot flashes and sweating are among the most frequent ADT adverse effects.

They can range from mild warmth to repeated episodes that disturb sleep or quality of life.

Treatment options exist when hot flashes are troublesome and should be discussed with the oncology team.

Bone Loss and Osteoporosis

Long-term androgen deprivation accelerates loss of bone mineral density and increases fracture risk.

Current EAU guidance recommends:

• assessing osteoporosis risk when long-term ADT begins;
• obtaining baseline bone mineral density with DEXA;
• monitoring bone health during treatment;
• checking calcium/vitamin D status; and
• using bone-protective treatment when indicated.

Weight-bearing/resistance exercise, smoking cessation and limiting excess alcohol are also important components of bone-health care.

Blood Sugar, Diabetes and Cholesterol

Current Lupron labeling warns that GnRH agonists can cause metabolic changes including:

• hyperglycemia;
• new or worsening diabetes;
• hyperlipidemia; and
• postmarketing cases of non-alcoholic fatty liver disease.

Patients should therefore have appropriate monitoring of:

• fasting glucose and/or HbA1c;
• lipid profile;
• weight and waist/body composition; and
• blood pressure.

The old page incorrectly listed hypoglycemia as though it were the main Lupron metabolic concern. The more important chronic issue is metabolic syndrome and hyperglycemia/diabetes risk.

Cardiovascular Risk

Current prescribing information warns that myocardial infarction, sudden cardiac death and stroke have been reported in association with GnRH agonists.

The absolute risk varies with the patient’s existing cardiovascular health.

Men with:

• known coronary disease;
• previous stroke;
• diabetes;
• hypertension;
• smoking history; or
• other major cardiovascular risk factors

may need closer cardiovascular risk assessment and management.

EAU recommends cardiovascular screening and at least cardiology input for men with a history of cardiovascular disease starting ADT.

QT Prolongation and Heart Rhythm

Androgen deprivation can prolong the QT/QTc interval.

Extra caution is appropriate in men with:

• congenital long-QT syndrome;
• heart failure;
• frequent low potassium or magnesium;
• significant arrhythmia history; or
• other medicines that prolong QT.

Current labeling advises consideration of ECG and electrolyte monitoring when clinically appropriate.

Anemia and Fatigue

ADT can lower hemoglobin and contribute to fatigue.

EAU includes hemoglobin monitoring in follow-up of men receiving long-term ADT.

Fatigue can also result from cancer itself, sleep disturbance, anemia, metabolic changes, depression or other treatments, so persistent or severe fatigue deserves assessment.

Depression, Mood and Cognitive Effects

Long-term androgen deprivation can affect mood, energy and quality of life.

Depression and cognitive complaints may occur in some patients, although these symptoms can also be influenced by cancer burden, age, sleep, other medicines and medical comorbidities.

Significant mood deterioration should be discussed with the treatment team rather than accepted as an unavoidable consequence of cancer therapy.

Convulsions

Current Lupron labeling includes postmarketing reports of convulsions.

Some affected patients had a history of epilepsy, stroke/CNS disease or medications that lower seizure threshold, but seizures have also been reported without known predisposing factors.

A new seizure requires urgent medical assessment.

Severe Skin Reactions

Current 2026 U.S. labeling includes an important warning for rare severe cutaneous adverse reactions, including:

• Stevens–Johnson syndrome/toxic epidermal necrolysis;
• DRESS; and
• acute generalized exanthematous pustulosis.

Allergic Reactions

Lupron Depot is contraindicated in people with known hypersensitivity to GnRH agonists or its formulation components.

Anaphylactic reactions have been reported.

Difficulty breathing, throat/facial swelling or collapse requires emergency care.

Does Lupron Cause Pneumonia or Pulmonary Fibrosis?

The legacy page lists pneumonia and pulmonary fibrosis as though they are typical system-specific Lupron effects.

That is misleading.

Respiratory adverse events have been reported in clinical/postmarketing experience, but they are not the main predictable consequences of ADT.

New persistent cough or breathlessness still requires medical evaluation because men with advanced prostate cancer can also develop infection, pulmonary embolism, treatment toxicity or cancer-related lung complications.

How Is Lupron Treatment Monitored?

Monitoring should go beyond PSA alone.

Current EAU guidance recommends structured follow-up including:

• PSA;
• testosterone;
• blood count/hemoglobin;
• kidney function;
• liver tests;
• alkaline phosphatase where appropriate;
• lipids;
• fasting glucose/HbA1c;
• blood pressure and cardiovascular risk;
• bone mineral density;
• treatment symptoms and quality of life; and
• appropriate imaging according to disease state.

For metastatic disease, EAU recommends follow-up generally at least every 3–6 months with regular imaging.

Why Measure Testosterone During Lupron Treatment?

PSA falling does not prove testosterone is adequately suppressed.

EAU considers testosterone monitoring standard practice during ADT because a minority of men fail to achieve or maintain expected castrate levels.

If prostate cancer appears to progress, testosterone should be checked before labeling the disease castration-resistant.

Lupron vs GnRH Antagonists

Does Lupron Still Work After Many Years?

Lupron can continue suppressing testicular testosterone even after cancer becomes castration-resistant.

The problem in castration-resistant disease is not necessarily failure of Lupron to lower testosterone. Instead, cancer cells develop mechanisms that allow them to grow despite low circulating testosterone.

That is why ADT is usually continued while another treatment is added.

When Should You Contact the Cancer Team Urgently?

Questions to Ask Before Starting Lupron

1. Why is ADT indicated for my exact stage and risk group?
2. How long will I need Lupron?
3. Am I at risk of testosterone flare?
4. Do I need temporary anti-androgen treatment at the start?
5. Would a GnRH antagonist be more appropriate?
6. Should Lupron be combined with an ARPI, radiotherapy or chemotherapy?
7. What are my baseline testosterone and PSA?
8. Do I need a DEXA bone-density scan?
9. How will my glucose, cholesterol and cardiovascular risk be monitored?
10. What symptoms should make me call urgently?

Medical information notice: Lupron Depot is prescription cancer therapy and must be administered according to an oncology/urology treatment plan. This article is educational and does not replace specialist treatment decisions.